Inventor · disambiguated record
Andrew Polson
Also filed as: POLSON ANDREW · POLSON ANDREW G
50 granted patents·48 pending applications·483 citations·filing 2003–2025
98Inventor score
Top patents by PatentIndex Score
98 records- 0197US8545850B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2010·Granted Oct 1, 2013·48 cites·8 claims
- 0296US8088378B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2008·Granted Jan 3, 2012·48 cites·5 claims
- 0395US9896506B2Anti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2015·Granted Feb 20, 2018·17 cites·27 claims
- 0495US9562099B2Anti-B7-H4 antibodies and immunoconjugatesGENENTECH INC·Filed 2014·Granted Feb 7, 2017·16 cites·17 claims
- 0595US8617559B2Anti-FcRH5 antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2012·Granted Dec 31, 2013·19 cites·34 claims
- 0694US8722857B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2009·Granted May 13, 2014·22 cites·53 claims
- 0794US8691531B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2011·Granted Apr 8, 2014·20 cites·9 claims
- 0894US8362213B2Anti-FcRH5 antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2010·Granted Jan 29, 2013·28 cites·53 claims
- 0993US11286302B2Anti-B7-H4 antibodies and immunoconjugatesGENENTECH INC·Filed 2018·Granted Mar 29, 2022·4 cites·36 claims
- 1093US9975949B2Anti-CD79b antibodies and methods of useGENENTECH INC·Filed 2015·Granted May 22, 2018·13 cites·31 claims
- 1193US8389697B2Anthracycline derivative conjugates, process for their preparation and their use as antitumor compoundsBERIA ITALO·Filed 2012·Granted Mar 5, 2013·34 cites·15 claims
- 1292US10981987B2Humanized anti-CD79b antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2017·Granted Apr 20, 2021·4 cites·26 claims
- 1392US10059768B2Anti-B7-H4 antibodies and immunoconjugatesGENENTECH INC·Filed 2015·Granted Aug 28, 2018·9 cites·19 claims
- 1492US9951133B2Anti-CD33 antibodies and immunoconjugatesGENENTECH INC·Filed 2016·Granted Apr 24, 2018·12 cites·51 claims
- 1592US9845355B2Humanized anti-CD79b antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2008·Granted Dec 19, 2017·20 cites·23 claims
- 1692US8466260B2Anti-FcRH5 antibodies and immunoconjugates and methods of useELKINS KRISTI·Filed 2010·Granted Jun 18, 2013·21 cites·49 claims
- 1791US11230600B2Anti-B7-H4 antibodies and immunoconjugatesGENENTECH INC·Filed 2018·Granted Jan 25, 2022·3 cites·23 claims
- 1891USRE48558EAnti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2018·Granted May 18, 2021·2 cites·70 claims
- 1991US9360484B2Anti-FcRH5 antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2013·Granted Jun 7, 2016·7 cites·20 claims
- 2091US8900589B2Anthracycline derivative conjugates, process for their preparation and their use as antitumor compoundsBERIA ITALO·Filed 2009·Granted Dec 2, 2014·23 cites·20 claims
- 2190US10150813B2Anti-B7-H4 antibodies and immunoconjugatesGENENTECH INC·Filed 2014·Granted Dec 11, 2018·12 cites·55 claims
- 2290US7858330B2Compositions and methods for the treatment of tumor of hematopoietic originGENENTECH INC·Filed 2006·Granted Dec 28, 2010·15 cites·20 claims
- 2389US11866496B2Humanized anti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2021·Granted Jan 9, 2024·1 cites·31 claims
- 2489US7888478B2Compositions and methods for the treatment of tumor of hematopoietic originGENENTECH INC·Filed 2005·Granted Feb 15, 2011·15 cites·92 claims
- 2589US2024309088A1Anti-cd79b antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2023·Application pending·0 cites
- 2688US10544218B2Anti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2016·Granted Jan 28, 2020·4 cites·61 claims
- 2788US9695240B2Anthracycline derivative conjugates, process for their preparation and their use as antitumor compoundsGENENTECH INC·Filed 2014·Granted Jul 4, 2017·11 cites·9 claims
- 2887US10501545B2Anti-CLL-1 antibodies and methods of useGENENTECH INC·Filed 2016·Granted Dec 10, 2019·6 cites·31 claims
- 2986US11000510B2Methods of using anti-CD79b immunoconjugatesGENENTECH INC·Filed 2019·Granted May 11, 2021·2 cites·49 claims
- 3086US10494432B2Anti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2013·Granted Dec 3, 2019·5 cites·118 claims
- 3186US7754441B2Compositions and methods for the treatment of tumor of hematopoietic originGENENTECH INC·Filed 2006·Granted Jul 13, 2010·10 cites·11 claims
- 3285US12016842B2Methods of using anti-CD79b immunoconjugatesGENENTECH INC·Filed 2021·Granted Jun 25, 2024·1 cites·18 claims
- 3385US10266597B2Anti-CLL-1 antibodies and immunoconjugatesGENENTECH INC·Filed 2017·Granted Apr 23, 2019·3 cites·99 claims
- 3485US9017951B2Anti-FcRH5 antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2012·Granted Apr 28, 2015·7 cites·1 claims
- 3585US8388973B2Compositions and methods for the treatment of tumor of hematopoietic originCHANG WESLEY·Filed 2010·Granted Mar 5, 2013·7 cites·58 claims
- 3683US2025073212A1METHODS OF USING ANTI-CD79b IMMUNOCONJUGATESGENENTECH INC·Filed 2024·Application pending·0 cites
- 3782US9175089B2Anti-LGR5 antibodies and immunoconjugatesGENENTECH INC·Filed 2013·Granted Nov 3, 2015·5 cites·31 claims
- 3882US2022251197A1Anti-cd79b antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2022·Application pending·0 cites
- 3981US10639378B2Silvestrol antibody-drug conjugates and methods of useGENENTECH INC·Filed 2017·Granted May 5, 2020·1 cites·7 claims
- 4080US12281165B2Anti-B7-H4 antibodies and immunoconjugatesGENENTECH INC·Filed 2022·Granted Apr 22, 2025·0 cites·20 claims
- 4180US2025297011A1Anti-B7-H4 Antibodies and ImmunoconjugatesGENENTECH INC·Filed 2025·Application pending·0 cites
- 4279US12134649B2Anti-B7-H4 antibodies and immunoconjugatesGENENTECH INC·Filed 2021·Granted Nov 5, 2024·0 cites·20 claims
- 4379US2022298161A1Pyrrolobenzodiazepines and conjugates thereofMEDIMMUNE LTD·Filed 2022·Application pending·0 cites
- 4478US10239947B2Anti-CLL-1 antibodies and immunoconjugatesGENENTECH INC·Filed 2017·Granted Mar 26, 2019·1 cites·80 claims
- 4578US10227412B2Anti-CLL-1 antibodies and immunoconjugatesGENENTECH INC·Filed 2017·Granted Mar 12, 2019·1 cites·18 claims
- 4677US10435471B2Anti-FcRH5 antibodiesGENENTECH INC·Filed 2014·Granted Oct 8, 2019·3 cites·49 claims
- 4776US2020247887A1Anti-cd79b antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2019·Application pending·0 cites
- 4875US10556951B2Anti-CD33 antibodies and immunoconjugatesGENENTECH INC·Filed 2018·Granted Feb 11, 2020·1 cites·39 claims
- 4975US9751946B2Anti-CLL-1 antibodies and immunoconjugatesGENENTECH INC·Filed 2015·Granted Sep 5, 2017·1 cites·96 claims
- 5074US2023096941A1Anti-fcrh5 antibodiesGENENTECH INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 98 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Andrew Polson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →